Summit Therapeutics/$SMMT
1D1W1MYTD1Y5YMAX
About Summit Therapeutics
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
- Ticker
- $SMMT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 265
- Headquarters
- Miami, United States
- Website
- www.smmttx.com
SMMT Metrics
BasicAdvanced
$10B
-
-$1.12
-1.26
-
Price and volume
Market cap
$10B
Beta
-1.26
52-week high
$30.05
52-week low
$12.07
Average daily volume
4.5M
Financial strength
Current ratio
6.958
Quick ratio
6.669
Long term debt to equity
2.672
Total debt to equity
3.236
Profitability
EBITDA (TTM)
-874.67
Management effectiveness
Return on assets (TTM)
-101.61%
Return on equity (TTM)
-192.50%
Valuation
Price to book
16.57
Price to tangible book (TTM)
16.62
Price to free cash flow (TTM)
-21.921
Free cash flow yield (TTM)
-4.56%
Free cash flow per share (TTM)
-0.6
Growth
Earnings per share change (TTM)
10.27%
3-year earnings per share growth (CAGR)
-8.26%
What the Analysts think about SMMT
Analyst ratings (Buy, Hold, Sell) for Summit Therapeutics stock.
SMMT Financial Performance
Revenues and expenses
SMMT Earnings Performance
Company profitability
SMMT News
AllArticlesVideos
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer
Business Wire1 week ago
These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks
Barrons2 weeks ago
Jim Cramer Calls Summit Therapeutics A 'Great Spec,' Recommends Buying This Consumer Cyclical Stock
Benzinga3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.